Table 2.

Characteristics Associated with Planned Opioid Agonist Treatment (OAT) During Detoxification, 2015

Admission Characteristics	OAT Planned (%)	No OAT Planned (%)	AOR	95% CI	Wald Chi-square	p-value
Sex
Male	10.4	89.6	Ref	Ref	-	-
Female	12.2	87.8	1.01	0.93-1.11	0.06	0.814
Age
25 and Under	10.0	90.0	Ref	Ref	-	-
26-54	10.5	89.5	1.19*	1.06-1.32	9.23	0.002
55 and Older	21.0	79.0	1.51*	1.19-1.91	11.42	0.001
Race
White	10.4	89.6	2.82*	2.30-3.46	100.42	<0.001
Black/African American	13.0	87.0	2.56*	2.01-3.30	56.65	<0.001
All Other	12.9	87.1	Ref	Ref	-	-
Housing Status
Dependent/Independent	12.3	87.7	Ref	Ref	-	-
Homeless	6.7	93.3	0.53*	0.47-0.59	117.94	<0.001
Psychiatric Comorbidity
No	17.5	82.5	Ref	Ref	-	-
Yes	12.4	87.6	0.59*	0.53-0.63	159.52	<0.001
Prior Treatment Episodes
0	17.1	82.9	0.63*	0.56-0.71	58.41	<0.001
1-3	18.4	81.6	Ref	Ref	-	-
4 or more	10.3	89.7	0.56*	0.51-0.62	141.34	<0.001
Insurance
Private Insurance	21.6	78.4	Ref	Ref	-	-
Medicaid	8.7	91.3	0.41*	0.36-0.47	179.24	<0.001
Medicare	6.6	93.4	0.28*,a	0.24-0.37	197.56	<0.001
No Insurance	6.8	93.2	0.39*	0.34-0.45	179.72	<0.001

Results represent the percent of patients admitted to detoxification centers in the U.S. in 2015 for which methadone or buprenorphine was planned as part of their treatment regimen. Outcomes are presented according to Treatment Episode Data Set - Admissions (TEDS-A) response options. A generalized linear model with logit link function was used to assess patient characteristics that impacted the odds of having methadone or buprenorphine treatment planned as part of detoxification.

^*denotes significant AOR (p<0.05). AOR < 1.00 suggests patients had lower odds of receiving medication. 95% CI=95% Confidence Interval; AOR=adjusted odds ratio; OAT=opioid agonist treatment; Ref=reference variable within each category.

^aSignificantly different from all other insurance types after within-category Bonferroni correction